The information you provide to the chat will be collected and recorded to improve your experience and for quality assurance. Please read our privacy policy to see how we are storing and protecting your data.
How can we help you today?
Discover our new oral solid dose (OSD) development capabilities at our Bend, Oregon site.
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Recent searches
Clear History
Suggestions
All Results
Search
US | EN
Within early development, there are a variety of different challenges that hinder a molecule’s ability to progress to the next phase such as complex formulation.
The complexity of sterile drug development has been on the rise, which is driven by a variety of different factors. Complex formulation trends are being driven by the industries focus on:
- Orphan drugs: This market is projected to grow at 13% CAGR from 2020-2024
- mRNA therapeutics: Prior to the COVID-19 Pandemic, the global mRNA therapeutics market was estimated to reach ~3B by 2026
- Repurposed drugs: Costs of bringing a repurposed drug to market have been estimated to be US$300 million on average, compared with an estimated ~$2–3 billion for a new chemical entity